| abstract |
A compound with antiestrogenic activity for use in a method of treating BC or other estrogen-responsive tumors in a human patient, wherein the method comprises subjecting the patient to a fasting-mimicking diet for a period of 24-190 hours, Concomitant treatment of patients with compounds with anti-estrogenic activity, which may be selective estrogen receptor modulators (SERMs), selective estrogen receptor down-regulators (SERDs), or aromatase inhibitors (AIs) . |